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Abstract
Objective: To evaluate the feasibility of the off-bypass implantation of a self-expandable valved stent of large size in pulmonary position.
Materials and methods: A glutaraldehyde preserved valved bovine jugular xenograft with internal diameter ¼ 22 mm, mounted in two
rings of nitinol ‘Z’ stent, expandable from 7 to 24 mm of internal diameter, was acutely evaluated in 6 adult pigs, mean body weight 55.6 kg
(range 47–67 kg). Through a stent-graft delivery system (24 French) the self expandable valved stent was implanted off-bypass in pulmonary
valve position by trans-ventricular approach through median sternotomy. Results: The mean diameter of the main pulmonary artery
measured was 21.7 ^ 1.6 mm. The mean length of the self expandable valved stent was 23.1 ^ 0.7 mm, the mean internal diameter
21.6 ^ 0.7 mm and the mean external diameter 26.3 ^ 0.7 mm. The mean peak pressure gradient recorded across the valve was
6.33 ^ 2.8 mmHg (range 4.5–9.6 mmHg) at Doppler echocardiography, and 4.5 ^ 3.1 mmHg (range 0–7 mmHg) at invasive
measurement, with a pulmonary blood flow of 3.03 ^ 0.05 l/min. Intra-vascular ultrasound showed complete opening and closure of the
valve (mean area reduction from 315.08 ^ 54.13 to 0 mm2). Conclusions: (a) Off-bypass implantation of self-expandable valved stent is
feasible in pulmonary position; (b) off-bypass surgical approach allows for valved stent implantation of adult size with adequate
hemodynamic functioning; and (c) intra-vascular ultrasound makes implantation and evaluation easy and reproducible.
q 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
After previous experimental studies with percutaneous
valve replacement in pulmonary [1] and aortic [2,3]
position, the percutaneous insertion of a biological valve
in pulmonary position has been introduced in the clinical
practice [4,5].
Insertion of a valve in pulmonary position is indicated
mainly in two situations: (a) pulmonary valve regurgitation,
generally after surgical repair for tetralogy of Fallot [6–14];
and (b) dysfunction of the biological valved conduit pre-
viously implanted to establish the continuity between the
right ventricle and the pulmonary artery during repair of
complex congenital heart defects [15,16].
So far the conventional treatment for the above situations
consisted in pulmonary valve replacement [6–14] and
replacement of the biological valved conduit [15–17], even
if with uncertainty about the adequate timing for pulmonary
valve insertion in order to prevent or reduce the incidence of
sudden death, arrhythmias and right ventricular dysfunction
[5–14].
Several alternative strategies, particularly in the presence
of a dysfunction of a biological valved conduit, have been
considered within the last years, including other types of
biological valved conduits [18–20] or endovascular stent
implantation to dilate and delay the surgical replacement of
the obstructed conduit [21–23].
The main limit in the use of endovascular stents to dilate
an obstructed biological conduit implanted between the
right ventricle and the pulmonary artery is that, even if the
obstruction is relieved or substantially reduced without
requiring for a re-operation on cardiopulmonary bypass,
the patient remains with a pulmonary valve regurgitation,
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frequently worse than before. The subsequent right ven-
tricular volume overload can cause irreversible myocardial
damages, with the known incidence of sudden death,
arrhythmias and right ventricular dysfunction [5–14,24].
The advantages of the percutaneous insertion of the
pulmonary valve over the conventional surgical techniques
are quite evident in terms of avoiding an operation on
cardiopulmonary bypass, and in the same time in the ability
of implanting a functioning valve, therefore reducing or
abolishing both the pressure and the volume overload on the
right ventricle [1,4,5]. The major limit of this recently
reported technique is the mismatch between size of the
venous access and size of the introducer (at least 18 Fr),
restricting the use of this strategy to older children and the
size of the valve to an 18 mm internal diameter biological
valve [5].
Because of the above problems, we devised an experi-
mental study to evaluate an alternative strategy aiming at
the off-bypass implantation of a self-expandable valved
stent of large size in pulmonary position from right
ventricular approach.
2. Materials and methods
A glutaraldehyde preserved valved bovine jugular xeno-
graft with internal diameter ¼ 22 mm was mounted in two
rings of non-thermosensitive nitinol ‘Z’ stents, expandable
from 7 to 24 mm of internal diameter. In vitro static per-
formance and dynamic test evaluation of this valved stent
have been already reported [25]. The self expanding valved
stent was prepared with a Teflon sheath stent-graft delivery
system with overall diameter 8.0 mm ¼ 24 F.
Acute in vivo evaluation was performed in six adult pigs,
mean body weight 55.6 kg (range 47–67 kg). After general
anaesthesia, tracheal intubation and mechanical ventilation,
with continuous monitoring of electrocardiogram, arterial
and central venous pressure and oxygen saturation, the chest
was opened through a conventional median sternotomy.
Heparin was administered i.v. (1 mg/kg). After a short
incision (4 mm) on the anterior aspect of the right ventricle,
controlled by a purse string on 4-0 polypropylene suture,
through the sheath stent-graft delivery system the valved
stent was implanted off-bypass in pulmonary valve
position by trans-ventricular approach (Fig. 1). The correct
positioning of the valved stent was evaluated and confirmed
before definitive deployment by intravascular ultrasound
technique.
Valve function was assessed with colour Doppler
echocardiography, flow and pressure drop measurements
with Swan-Ganz Oximetry (Baxter-Edwards, CA, USA)
catheter, as well as intravascular ultrasound (Boston
Scientific Corporation, CA, USA) with a 6F, 12.5 MHz
transducer and Acuson Corporation, CA, USA) with 10F,
7.5 MHz transducer in real time.
A high fidelity tip mounted Millar pressure transducer
system was used to invasively measure the pressure
proximal and distal to the valve.
At the end of the study the animals were electively
sacrificed to check the adequate position of the valved stent,
as well as its deployment and anchorage and the presence of
any deformation of the valve.
All animals received human care in compliance with the
‘Principles of Laboratory Animals’ formulated by the
National Society of Medical Research and the ‘Guide for
the Care and Use of Laboratory Animals’ prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH publication 85-23,
revised 1985). The protocol was approved by the insti-
tutional Committee on Animal Research.
Statistical analysis: the Student’s t-test was utilized, and
all data were expressed as mean ^ standard deviation.
3. Results
The mean diameter of the main pulmonary artery
measured with intravascular ultrasound was 21.7 ^
1.6 mm. The mean length of the valved stent was 23.1 ^
0.7 mm, the mean internal diameter 21.6 ^ 0.7 mm and the
mean external diameter 26.3 ^ 0.7 mm.
The mean peak pressure gradient recorded across the
valve was 6.33 ^ 2.8 mmHg (range 4.5–9.6 mmHg) at
Doppler echocardiography, and 4.5 ^ 3.1 mm Hg (range
0 – 7 mmHg) at invasive measurement, with a mean
pulmonary blood flow of 3.03 ^ 0.05 l/min.
Intravascular ultrasound showed complete opening
and closure of the valve (mean area reduction from
Fig. 1. After a short incision (4 mm) on the anterior aspect of the right
ventricle, controlled by a purse string on 4-0 polypropylene suture, through
the sheath stent-graft delivery system the valved stent has been implanted
off-bypass in pulmonary valve position by trans-ventricular approach.
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315.08 ^ 54.13 to 0 mm2) (Fig. 2). In all animals Doppler
echocardiography confirmed the absence of any valve
regurgitation as well as of paravalvular leak (Fig. 3).
No significant changes were recorded in electrocardio-
gram, arterial and central venous pressure and oxygen satu-
ration after self expandable valved stent implantation.
Post-mortem examination confirmed the adequate posi-
tion of the valved stent in pulmonary position (Fig. 4), as
well as ruled out any valve deformation or thrombus (Fig. 5).
4. Discussion
The implant of a valve in pulmonary position has the
ideal purpose of abolishing the pulmonary valve regurgita-
tion to prevent or reduce the incidence of sudden death,
arrhythmias and right ventricular dysfunction [5–14] with
the lowest possible surgical risk.
Because of the difficult balance between costs (risks) and
benefits (competent pulmonary valve), timing and type of
management so far have not reach general agreement [24].
The percutaneous insertion of a pulmonary valve,
recently introduced in the clinical practice [4,5], presents
the advantages of avoiding an operation on cardio-
pulmonary bypass and in the same time the possibility
of implanting a functioning valve, therefore reducing or
abolishing both the pressure and the volume overload on
the right ventricle [1,4,5]. The major current limit of this
technique is the mismatch between size of the venous
access and size of the introducer (at least 18 Fr),
restricting the use to older children (.25 kg of body
weight) and the size of the valve to an 18 mm internal
diameter biological valve [5].
Our experimental study proposes an alternative strategy
allowing the off-bypass implantation of a self-expandable
valved stent of large size (internal diameter ¼ 22 mm) in
pulmonary position from right ventricular approach without
cardiopulmonary bypass.
The implant of a functioning pulmonary valve can
therefore been accomplished, overcoming the limits of the
currently available techniques, with the only additional risks
of a limited chest opening. In our initial experimental study
Fig. 2. Intravascular ultrasound showing complete opening (A); and closure (B) of the valve.
Fig. 3. Doppler echocardiography confirming the absence of any valve regurgitation as well as of paravalvular leak.
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we used a median sternotomy because we wanted to
evaluated the feasibility of the new technique. In fact, based
on this first experience, the implant of the valved stent in
pulmonary position can be accomplished through a limited
left anterior thoracotomy, particularly advantageous in
clinical practice in the presence of a previous median
sternotomy.
With regard to the size of the valved stent, the mean
external diameter of 26.3 ^ 0.7 mm should allow adequate
implant even in patients with dilated right ventricular
outflow tract because of severe pulmonary valve regurgita-
tion, like the situation encountered years after repair of
tetralogy of Fallot with transannular patch.
With regard to the larger size of available biological
valve, the internal diameter of 22 mm, because of the
favourable effective orifice area, allows an adequate
Fig. 4. Post-mortem examination confirming the adequate position of the valved stent in pulmonary position (A); and showing the fingerprint of the Z stent on
the pulmonary artery wall (B).
Fig. 5. Post-mortem examination with the explanted valve in open (A); and closed (B) position, excluding any valve deformation or thrombus.
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hemodynamics without pressure gradient in patients up to
91 kg of body weight, as we already reported [26].
Of course our positive preliminary experimental data will
need to be validated by chronic studies.
4.1. Conclusions
(a) The off-bypass implantation of self-expandable
valved stent is feasible in pulmonary position; (b) the off-
bypass surgical approach allows for valved stent implan-
tation of adult size with adequate hemodynamic function-
ing; and (c) intravascular ultrasound makes implantation
and evaluation easy and reproducible.
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